000 04211nam a22005055i 4500
001 978-3-642-17907-5
003 DE-He213
005 20140220082844.0
007 cr nn 008mamaa
008 130810s2013 gw | s |||| 0|eng d
020 _a9783642179075
_9978-3-642-17907-5
024 7 _a10.1007/978-3-642-17907-5
_2doi
050 4 _aR-RZ
072 7 _aMBGR
_2bicssc
072 7 _aMED000000
_2bisacsh
082 0 4 _a610
_223
100 1 _aKlebe, Gerhard.
_eeditor.
245 1 0 _aDrug Design
_h[electronic resource] :
_bMethodology, Concepts, and Mode-of-Action /
_cedited by Gerhard Klebe.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg :
_bImprint: Springer,
_c2013.
300 _aXV, 901 p. 496 illus., 333 illus. in color. eReference.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aPart I  Fundamentalsin Drug Research -- 1. Drug Research Yesterday, Today and Tomorrow -- 2. The Role of Serendipityin Drug Research -- 3. Classical Drug Research -- 4. Protein–Ligand Interactionsas the Basis for Drug Action -- 5. Optical Activity and Biological Effects -- Part II Discovery and Optimizationof Lead Compounds --  6. Screeningfor Lead Structures -- 7.  Screening Technologies for LeadDiscovery -- 8. Optimizationof Lead Structures -- 9. Designingprodrugs -- 10. Peptidomimetics -- Part III  Experimental and Theoretical Methods -- 11. Combinatorics: Chemistry With Big Numbers -- 12. Gene Technology in drug research --  13. Experimental Methods of Structure Determination -- 14. The Spatial Structure of Biomolecules -- 15. Molecular Modelling -- 16. Conformational Analysis -- Part IV Structure–Activity Relationships and Design Approaches -- 17.Pharmacophore Hypothesis and Molecular Comparisons -- 18. Quantitative Structure–ActivityRelationships -- 19.  From in vitro to in vivo:Optimization of ADME-Tox Properties -- 20. ProteinModeling and Structure-BasedDrug Design -- 21.  ACase Study: Structure-Based Inhibtor Design for tRNA-Guanine Transglycosylase -- Part V. Drugs and drug action: Successes of stucture-based design -- 22. Howdrugs act: Concepts for therapy -- 23. Inhibitors of hydrolases With an acyl-enzymeintermediate -- 24. Asparticprotease inhibitors -- 25. Inhibitorsof hydrolysing metalloenzymes -- 26. Inhibitorsof transferases -- 27. Inhibitors ofoxidoreductases -- 28.  Agonists and antagonistsof nuclear receptors -- 29. Agonists and antagonists of membrane-bound -- 30. Ligands forchannels, pores and transporters -- 31. Ligands for surfacereceptors -- 32. Biologicals: Peptides, proteins, nucleotidesand macrolides as drugs.
520 _aUnique work on structure-based drug design, covering multiple aspects of drug discovery and development. Fully colored, many images, computer animations of 3D structures (these only in electronic form). Makes the spatial aspects of interacting molecules clear to the reader, covers multiple applications and methods in drug design. Structures by mode of action, no therapeutic areas. Of high relevance for academia and industrial research. Focus on gene technology in drug design, omics-technologies computational methods experimental techniques of structure determination multiple examples on mode of action of current drugs, ADME-tox properties in drug development, QSAR methods, combinatorial chemistry, biologicals, ribosome, targeting protein-protein interfaces.
650 0 _aMedicine.
650 0 _aToxicology.
650 0 _aPharmaceutical technology.
650 0 _aBiochemistry.
650 0 _aPharmacy.
650 1 4 _aBiomedicine.
650 2 4 _aBiomedicine general.
650 2 4 _aPharmacology/Toxicology.
650 2 4 _aPharmaceutical Sciences/Technology.
650 2 4 _aMedicinal Chemistry.
650 2 4 _aPharmacy.
650 2 4 _aMedicine/Public Health, general.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783642179068
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-17907-5
912 _aZDB-2-SBL
999 _c96752
_d96752